Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Lévy

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Therapie|December 19, 2021
Of some innovations in clinical trial design in hematology and oncologyVincent Lévy
Controlled Clinical Trials|December 31, 2002
Sample size correction for treatment crossovers in randomized clinical trials with a survival endpointRaphaël Porcher, Vincent Lévy, Sylvie Chevret
Hematology. American Society of Hematology. Education Program|December 10, 2021
Frontline treatment in CLL: the case for time-limited treatmentVincent Lévy, Alain Delmer, Florence Cymbalista
Journal of Clinical Epidemiology|November 18, 2008
A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trialAnne Hiance, Sylvie Chevret, Vincent Lévy
BMC Medical Research Methodology|May 28, 2026
Information borrowing in phase II randomized dose-ranging clinical trials in oncologyGuillaume Mulier, Vincent Lévy, Lucie Biard
Leukemia & Lymphoma|March 24, 2026
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferredVincent Lévy, Etienne Lengline, Sylvie Chevret
Molecular Therapy. Advances|July 16, 2026
Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature reviewLucie Biard, Vincent Lévy, Sylvie Chevret, et al.
Leukemia Research|December 20, 2008
How to use clinical vignettes in hematology--a pilot survey in the context of chronic lymphocytic leukemiaSandra M Camps, Sylvie Chevret, Vincent Lévy
Contemporary Clinical Trials Communications|January 29, 2021
Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trialsLucie Biard, Anne Bergeron, Vincent Lévy, et al.
Patient Preference and Adherence|December 7, 2018
Disruption in time projection and non-adherence to long-term therapiesGérard Reach, Marouane Boubaya, Yoann Brami, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Therapie|December 19, 2021
Of some innovations in clinical trial design in hematology and oncologyVincent Lévy
Controlled Clinical Trials|December 31, 2002
Sample size correction for treatment crossovers in randomized clinical trials with a survival endpointRaphaël Porcher, Vincent Lévy, Sylvie Chevret
Hematology. American Society of Hematology. Education Program|December 10, 2021
Frontline treatment in CLL: the case for time-limited treatmentVincent Lévy, Alain Delmer, Florence Cymbalista
Journal of Clinical Epidemiology|November 18, 2008
A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trialAnne Hiance, Sylvie Chevret, Vincent Lévy
BMC Medical Research Methodology|May 28, 2026
Information borrowing in phase II randomized dose-ranging clinical trials in oncologyGuillaume Mulier, Vincent Lévy, Lucie Biard
Leukemia & Lymphoma|March 24, 2026
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferredVincent Lévy, Etienne Lengline, Sylvie Chevret
Molecular Therapy. Advances|July 16, 2026
Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature reviewLucie Biard, Vincent Lévy, Sylvie Chevret, et al.
Leukemia Research|December 20, 2008
How to use clinical vignettes in hematology--a pilot survey in the context of chronic lymphocytic leukemiaSandra M Camps, Sylvie Chevret, Vincent Lévy
Contemporary Clinical Trials Communications|January 29, 2021
Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trialsLucie Biard, Anne Bergeron, Vincent Lévy, et al.
Patient Preference and Adherence|December 7, 2018
Disruption in time projection and non-adherence to long-term therapiesGérard Reach, Marouane Boubaya, Yoann Brami, et al.
Pageof 7